Clearside Biomedical

Clearside Biomedical EV/EBIT

Delisted

The EV/EBIT (Enterprise Value to EBIT) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -0.12. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.14 — a change of -13.98% (higher).

EV/EBIT

-0.12

YoY

-13.98%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Clearside Biomedical is 2024 -0.12 . EV/EBIT (Enterprise Value to EBIT) of Clearside Biomedical was 2023 -0.14 . It decreases by -13.98% higher compared to the previous year.

The Clearside Biomedical EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-0.12 USD
Jan 1, 2020
-0.20 USD
Jan 1, 2021
-5.68 USD
Jan 1, 2022
-0.12 USD
Jan 1, 2023
-0.14 USD
Jan 1, 2024
-0.12 USD
Jan 1, 2025 (e)
-0.02 USD
Jan 1, 2026 (e)
-0.14 USD
The Clearside Biomedical EV/EBIT history
YEAREV/EBITYoY
est-0.14+600.00%
est-0.02-83.59%
-0.12-13.98%
-0.14+21.88%
-0.12-97.95%
-5.68+2,793.55%
-0.20+68.90%
-0.12+173.76%
-0.04-29.58%
-0.06-56.86%
-0.14-31.27%
-0.20-43.30%
-0.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Clearside Biomedical's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Clearside Biomedical's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Clearside Biomedical's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Clearside Biomedical grows earnings faster than its peers.

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

EV/EBIT (Enterprise Value to EBIT) of Clearside Biomedical is -0.12 in 2024.

EV/EBIT (Enterprise Value to EBIT) of Clearside Biomedical changed from -0.14 to -0.12, representing a -13.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Clearside Biomedical

All Key Metrics — Clearside Biomedical